Skip to main content

Table 2 The patients’ clinicopathological parameters and comparisons of them between the two groups

From: Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients

Clinicopathological parameters Group A (HLNs <22; N = 157), n (%) Group B (HLNs ≥22; N = 242), n (%) P-value
Sex    0.504
 Male 110 (70.1) 177 (73.1)  
 Female 47 (29.9) 65 (26.9)  
Age    0.108
 ≤60 89 (56.7) 147 (60.7)  
 >60 68 (43.3) 95 (39.3)  
BMI    0.732
 <19 13 (8.4) 18 (7.7)  
 ~ < 25 93 (60.4) 154 (65.5)  
 ~ < 30 43 (27.9) 58 (24.7)  
 ≥30 5 (3.2) 5 (2.1)  
NACT    0.392
 No 114 (72.6) 166 (68.6)  
 Yes 43 (27.4) 76 (31.4)  
Differentiation    0.003
 Well 12 (8.5) 11 (4.8)  
 Moderate 90 (63.4) 113 (49.8)  
 Poor 40 (28.2) 103 (45.4)  
LVI    0.834
 No 139 (88.5) 213 (88.0)  
 Yes 18 (11.5) 29 (12.0)  
Tumour size    <0.001
 ≤5 cm 146 (95.4) 196 (83.4)  
 >5 cm 7 (4.6) 39 (16.6)  
Gastrectomy    <0.001
 Distal 84 (54.2) 145 (59.9)  
 Proximal 48 (31.0) 23 (9.5)  
 Total 23 (14.8) 74 (30.6)  
T stagea    0.003
 T1 65 (43.6) 64 (27.6)  
 T2 37 (24.8) 53 (22.8)  
 T3 1 (0.7) 2 (0.9)  
 T4 46 (30.9) 113 (48.7)  
  1. HLNs harvested lymph nodes, BMI body mass index, NACT neoadjuvant chemotherapy, LVI lymphovascular invasion
  2. a7th AJCC TNM staging system for gastric cancer